CO2024001992A2 - Composiciones para el tratamiento de la vaginosis bacteriana - Google Patents

Composiciones para el tratamiento de la vaginosis bacteriana

Info

Publication number
CO2024001992A2
CO2024001992A2 CONC2024/0001992A CO2024001992A CO2024001992A2 CO 2024001992 A2 CO2024001992 A2 CO 2024001992A2 CO 2024001992 A CO2024001992 A CO 2024001992A CO 2024001992 A2 CO2024001992 A2 CO 2024001992A2
Authority
CO
Colombia
Prior art keywords
bacterial vaginosis
treatment
compositions
composition
vaginosis
Prior art date
Application number
CONC2024/0001992A
Other languages
English (en)
Inventor
David Friend
Jennifer Kiang
Nicolas J Pacelli
Mark Walters
Original Assignee
Dare Bioscience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dare Bioscience Inc filed Critical Dare Bioscience Inc
Publication of CO2024001992A2 publication Critical patent/CO2024001992A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Una composición farmacéutica para uso en el tratamiento de la vaginosis bacteriana, en donde dicha composición comprende un poloxámero, un polímero de estabilización y un ingrediente activo para tratar la vaginosis bacteriana, preferentemente clindamicina, en donde dicha composición tiene una viscosidad de al menos 1,5 millones mPa.s.
CONC2024/0001992A 2021-07-26 2024-02-22 Composiciones para el tratamiento de la vaginosis bacteriana CO2024001992A2 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163225872P 2021-07-26 2021-07-26
US202163285442P 2021-12-02 2021-12-02
US202263331744P 2022-04-15 2022-04-15
PCT/US2022/038201 WO2023009445A1 (en) 2021-07-26 2022-07-25 Compositions for use in the treatment of bacterial vaginosis

Publications (1)

Publication Number Publication Date
CO2024001992A2 true CO2024001992A2 (es) 2024-04-18

Family

ID=82898805

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2024/0001992A CO2024001992A2 (es) 2021-07-26 2024-02-22 Composiciones para el tratamiento de la vaginosis bacteriana

Country Status (8)

Country Link
US (1) US20240165141A1 (es)
EP (1) EP4376852A1 (es)
KR (1) KR20240046191A (es)
AU (1) AU2022318739A1 (es)
CA (1) CA3227291A1 (es)
CO (1) CO2024001992A2 (es)
TW (1) TW202310848A (es)
WO (1) WO2023009445A1 (es)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030206958A1 (en) * 2000-12-22 2003-11-06 Cattaneo Maurizio V. Chitosan biopolymer for the topical delivery of active agents
US20060189552A1 (en) * 2000-12-12 2006-08-24 Mohan Vishnupad Dispenser for dispensing three or more actives
BRPI0709674A2 (pt) * 2006-03-31 2011-12-06 Stiefel Res Australia Pty Ltd gel de suspensão espumante
US20150352165A1 (en) * 2012-09-11 2015-12-10 Imuneks Farm Mac Sanayi Ve Ticaret A.S. Clindamycin phosphate, salicylic acid and tea tree oil combinations
NZ709209A (en) * 2012-12-20 2018-07-27 Smilesonica Inc Internal ultrasound gel
PL3324938T3 (pl) * 2015-07-20 2022-01-10 Trilogic Pharma Llc Preparaty do stosowania miejscowego i sposoby leczenia
US11071786B2 (en) * 2018-11-05 2021-07-27 Inspired Material Solutions, LLC Dermal skin protectant and carrier

Also Published As

Publication number Publication date
KR20240046191A (ko) 2024-04-08
US20240165141A1 (en) 2024-05-23
AU2022318739A1 (en) 2024-02-15
EP4376852A1 (en) 2024-06-05
WO2023009445A1 (en) 2023-02-02
CA3227291A1 (en) 2023-02-02
TW202310848A (zh) 2023-03-16

Similar Documents

Publication Publication Date Title
DOP2023000041A (es) Compuestos y métodos para el tratamiento de infecciones virales
AR054371A1 (es) Metodos y composiciones para manejo de desordenes psicoticos
CL2021003477A1 (es) Compuestos 2,3-dihidroquinazolin como inhibidores nav1 .8
EA202090868A1 (ru) Составы
CL2022003733A1 (es) Análogos de nucleósido de 1’-ciano y usos de los mismos
AR046824A1 (es) Composicion y aparato para la administracion transdermica.
CL2023000524A1 (es) Compuestos fosfolípidos y usos de los mismos
PE20040103A1 (es) Metodo y formas de dosificacion para incrementar la solubilidad de composiciones de farmaco para administracion controlada
CL2023001062A1 (es) Compuestos fosfolípidos y usos de estos
BR112022014660A2 (pt) Compostos terapêuticos, formulações e usos dos mesmos
CL2021000129A1 (es) Apirasas solubilizadas, métodos y usos
CL2020001856A1 (es) Métodos para tratar la enfermedad de farber.
UY31343A1 (es) Composicion con una combinacion de principios activos para el tratamiento del estrenimiento
CO2024001992A2 (es) Composiciones para el tratamiento de la vaginosis bacteriana
BR112018014723A2 (pt) fantasmas bacterianos para o tratamento de câncer
CL2021000107A1 (es) Métodos de tratamiento de hfpef empleando dapagliflozina y composiciones que comprenden la misma
MY192606A (en) Solid pharmaceutical compositions for treating hcv
AR126791A1 (es) Composición farmacéutica que comprende nanopartículas para la administración dirigida de antígenos
CO2018011420A2 (es) Formulaciones líquidas de fosfaplatino
UY39503A (es) Formulación sólida
CL2022001779A1 (es) Composiciones que comprenden aminoácidos para la prevención y/o el tratamiento del cáncer
MX2018000746A (es) Composiciones farmaceuticas solidas para el tratamiento del vhc.
AR109457A1 (es) Método para el tratamiento de la ame y composición farmacéutica
CL2019003172A1 (es) Brimonidina destinada al uso y diseño de ensayos clínicos para la atrofia geográfica debido a una degeneración macular asociada a la edad.
ES2507517T3 (es) Agente profiláctico o terapéutico para trastorno de déficit de atención con hiperactividad